Logo image of OVID

OVID THERAPEUTICS INC (OVID) Stock Fundamental Analysis

NASDAQ:OVID - Nasdaq - US6904691010 - Common Stock - Currency: USD

0.2857  0 (-1.41%)

After market: 0.2999 +0.01 (+4.97%)

Fundamental Rating

3

Overall OVID gets a fundamental rating of 3 out of 10. We evaluated OVID against 561 industry peers in the Biotechnology industry. OVID scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. OVID is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year OVID has reported negative net income.
In the past year OVID has reported a negative cash flow from operations.
OVID had negative earnings in 4 of the past 5 years.
In the past 5 years OVID reported 4 times negative operating cash flow.
OVID Yearly Net Income VS EBIT VS OCF VS FCFOVID Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

1.2 Ratios

Looking at the Return On Assets, with a value of -28.68%, OVID is in the better half of the industry, outperforming 67.38% of the companies in the same industry.
OVID has a Return On Equity of -38.74%. This is in the better half of the industry: OVID outperforms 71.12% of its industry peers.
Industry RankSector Rank
ROA -28.68%
ROE -38.74%
ROIC N/A
ROA(3y)-33.31%
ROA(5y)-29.01%
ROE(3y)-46.44%
ROE(5y)-51.69%
ROIC(3y)N/A
ROIC(5y)N/A
OVID Yearly ROA, ROE, ROICOVID Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OVID so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OVID Yearly Profit, Operating, Gross MarginsOVID Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

6

2. Health

2.1 Basic Checks

OVID does not have a ROIC to compare to the WACC, probably because it is not profitable.
OVID has more shares outstanding than it did 1 year ago.
The number of shares outstanding for OVID has been increased compared to 5 years ago.
OVID has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
OVID Yearly Shares OutstandingOVID Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
OVID Yearly Total Debt VS Total AssetsOVID Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -5.72, we must say that OVID is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -5.72, OVID is not doing good in the industry: 63.10% of the companies in the same industry are doing better.
OVID has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.72
ROIC/WACCN/A
WACC10.1%
OVID Yearly LT Debt VS Equity VS FCFOVID Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

OVID has a Current Ratio of 5.32. This indicates that OVID is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of OVID (5.32) is comparable to the rest of the industry.
A Quick Ratio of 5.32 indicates that OVID has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 5.32, OVID is in line with its industry, outperforming 58.47% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.32
Quick Ratio 5.32
OVID Yearly Current Assets VS Current LiabilitesOVID Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

OVID shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.05%, which is quite impressive.
OVID shows a strong growth in Revenue. In the last year, the Revenue has grown by 44.50%.
Measured over the past years, OVID shows a very negative growth in Revenue. The Revenue has been decreasing by -86.05% on average per year.
EPS 1Y (TTM)52.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.65%
Revenue 1Y (TTM)44.5%
Revenue growth 3Y-86.05%
Revenue growth 5YN/A
Sales Q2Q%-12.16%

3.2 Future

Based on estimates for the next years, OVID will show a very negative growth in Earnings Per Share. The EPS will decrease by -17.94% on average per year.
The Revenue is expected to grow by 162.85% on average over the next years. This is a very strong growth
EPS Next Y-61.86%
EPS Next 2Y-34.94%
EPS Next 3Y-34.8%
EPS Next 5Y-17.94%
Revenue Next Year-63.23%
Revenue Next 2Y-33.16%
Revenue Next 3Y-43.82%
Revenue Next 5Y162.85%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
OVID Yearly Revenue VS EstimatesOVID Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
OVID Yearly EPS VS EstimatesOVID Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OVID. In the last year negative earnings were reported.
Also next year OVID is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OVID Price Earnings VS Forward Price EarningsOVID Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OVID Per share dataOVID EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

A cheap valuation may be justified as OVID's earnings are expected to decrease with -34.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-34.94%
EPS Next 3Y-34.8%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OVID!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OVID THERAPEUTICS INC

NASDAQ:OVID (5/21/2025, 8:26:03 PM)

After market: 0.2999 +0.01 (+4.97%)

0.2857

0 (-1.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-11 2025-08-11/bmo
Inst Owners57.73%
Inst Owner Change-3.69%
Ins Owners5.24%
Ins Owner Change0.67%
Market Cap20.31M
Analysts87.69
Price Target3.26 (1041.06%)
Short Float %2.25%
Short Ratio3.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.52%
Min EPS beat(2)3.83%
Max EPS beat(2)23.22%
EPS beat(4)4
Avg EPS beat(4)50.89%
Min EPS beat(4)3.83%
Max EPS beat(4)152.99%
EPS beat(8)6
Avg EPS beat(8)-13.57%
EPS beat(12)9
Avg EPS beat(12)-5.33%
EPS beat(16)12
Avg EPS beat(16)-0.43%
Revenue beat(2)1
Avg Revenue beat(2)17%
Min Revenue beat(2)-60.64%
Max Revenue beat(2)94.64%
Revenue beat(4)3
Avg Revenue beat(4)78.57%
Min Revenue beat(4)-60.64%
Max Revenue beat(4)143.58%
Revenue beat(8)7
Avg Revenue beat(8)109.47%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10.98%
PT rev (3m)-1.84%
EPS NQ rev (1m)-1.99%
EPS NQ rev (3m)7.66%
EPS NY rev (1m)-7.3%
EPS NY rev (3m)7.94%
Revenue NQ rev (1m)-20%
Revenue NQ rev (3m)-55.56%
Revenue NY rev (1m)-10.37%
Revenue NY rev (3m)-34.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 35.88
P/FCF N/A
P/OCF N/A
P/B 0.3
P/tB 0.3
EV/EBITDA N/A
EPS(TTM)-0.35
EYN/A
EPS(NY)-0.69
Fwd EYN/A
FCF(TTM)-0.79
FCFYN/A
OCF(TTM)-0.79
OCFYN/A
SpS0.01
BVpS0.96
TBVpS0.96
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.68%
ROE -38.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.31%
ROA(5y)-29.01%
ROE(3y)-46.44%
ROE(5y)-51.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.26%
Cap/Sales 28.45%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.32
Quick Ratio 5.32
Altman-Z -5.72
F-Score4
WACC10.1%
ROIC/WACCN/A
Cap/Depr(3y)110.15%
Cap/Depr(5y)112.76%
Cap/Sales(3y)52.29%
Cap/Sales(5y)32.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.65%
EPS Next Y-61.86%
EPS Next 2Y-34.94%
EPS Next 3Y-34.8%
EPS Next 5Y-17.94%
Revenue 1Y (TTM)44.5%
Revenue growth 3Y-86.05%
Revenue growth 5YN/A
Sales Q2Q%-12.16%
Revenue Next Year-63.23%
Revenue Next 2Y-33.16%
Revenue Next 3Y-43.82%
Revenue Next 5Y162.85%
EBIT growth 1Y-4.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year9.56%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-22.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-22.23%
OCF growth 3YN/A
OCF growth 5YN/A